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Abstract
Abetalipoproteinemia (ABL, OMIM 200100) is a rare, autosomal recessive disorder, characterized
by fat malabsorption, acanthocytosis and hypocholesterolemia in infancy. Later in life, deficiency of
fat-soluble vitamins is associated with development of atypical retinitis pigmentosa, coagulopathy,
posterior column neuropathy and myopathy. ABL results from mutations in the gene encoding the
large subunit of microsomal triglyceride transfer protein (MTP; OMIM 157147). To date at least 33
MTP mutations have been identified in 43 ABL patients. We describe the clinical progress of two
patients, both currently in the fifth decade of life, who were diagnosed with ABL as children and
were treated with high oral doses of fat soluble vitamins, including vitamin E over the last three
decades. Treatment appears to have been associated with arrest of the neuropathy and other
complications in both patients. Because pharmacologic inhibition of MTP is being developed as a
novel approach to reduce plasma cholesterol for prevention of cardiovascular disease, defining the
long-term clinical features of patients with a natural deficiency in MTP might provide some insight
into the possible effects of such treatments. We review the range of clinical, biochemical and
molecular perturbations in ABL.
Background
Abetalipoproteinemia (ABL; OMIM 200100) is a rare met-
abolic disorder with a frequency <1 in 100,000. The clini-
cal association of peripheral blood acanthocytosis with
atypical retinitis pigmentosa and ataxia was first reported
by Bassen and Kornzweig in 1950 [1]. In 1958, Jampel
and Falls observed low serum cholesterol values in
affected individuals [2] and in 1960 Salt noticed the
absence of serum beta-lipoprotein in a patient with the
syndrome. Consequently the name of the disease was
changed to ABL [2]. Eventually, the fundamental bio-
chemical defect was determined to be a complete absence
of plasma apolipoprotein (apo) B-containing lipopro-
teins, namely chylomicrons, very-low density lipoprotein
(VLDL) and low-density lipoprotein (LDL). In 1986, the
APOB gene, its mRNA and the apo B content of the hepa-
tocytes were found to be normal in ABL patients, suggest-
ing that defective post-translational processing and
secretion of apo B was the cause of ABL [3]. In 1992, a
deficiency of microsomal triglyceride transfer protein
(MTP) activity was suggested to be the proximal cause of
ABL [4]. In 1993, the region on chromosome 4q22-24
that encodes the large subunit of MTP was cloned and
sequenced, and human MTP mutations in ABL patients
were reported [5].
The 894 amino-acid protein product of MTP (also called
97-KDa subunit) forms a heterodimer with the ubiqui-
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tous endoplasmic reticulum enzyme protein disulfide iso-
merase (PDI) [6]. MTP acts as a chaperone that facilitates
the transfer of lipids onto apo B. The MTP molecule is pre-
dicted to consist of three major structural domains: N-ter-
minal  β-barrel (residues 22–297), middle α-helical
(residues 298–603) and C-terminal domains (residues
604–894). The N-terminal β-barrel domain mediates the
interaction with the N terminus of apo B; the middle α-
helical domain mediates the interaction with both PDI
and apo B; and the C-terminal mediates the lipid-binding
and transfer catalytic activity of MTP.
Mutations that lead to the absence of a functional 97-KDa
subunit cause ABL. We describe the medical history of two
patients with ABL and summarize the range of reported
mutations and their associated clinical phenotypes.
Case presentations
Case #1
A 46 year old female of Northern European descent
(patient 1 in reference [7] and patient 27 in Additional file
1) was diagnosed with ABL at age 11, when she presented
with right ptosis. Medical work-up revealed acanthocyto-
sis on peripheral blood smear, which at the time was
pathognomonic for a diagnosis of ABL. Her ptosis was
corrected surgically. In retrospect, she had a history of
diarrhea in infancy that resolved upon fat restriction. She
was noted to have ataxia and paresthesia in a glove-and-
stocking distribution in her teenage years. She was started
on high oral doses of fat-soluble vitamins approximately
9 years after her diagnosis. In 1999, the molecular basis of
her condition was found to be a homozygous frameshift
mutation in exon 13 of MTP due to a single nucleotide
base-pair deletion (c.1820delG) [7].
At age 26 she married. At age 34, she gave birth to a full-
term healthy male infant. During her pregnancy, she was
advised to stop all intake of vitamin A to avoid the poten-
tial risk of vitamin A teratogenicity, despite the fact that
her serum beta-carotene concentration was below the
lower limit of the normal range. Postpartum, she devel-
oped a right corneal ulcer that required corneal transplan-
tation after a year. She was restarted on vitamin A
postpartum. Her corneal transplant failed and currently
she is waiting for a repeat right corneal transplant. Of
note, she was not able to achieve a second pregnancy
despite multiple attempts. Her past medical history
included scalp basal cell carcinoma successfully treated
with cryotherapy. She also had a long history of oli-
gomenorrhea. Subjectively, her symptoms had otherwise
remained stable for decades. Her parents were first cous-
ins. Her family history included two sisters with Alport
syndrome. There was no family history of ABL.
She was followed yearly and evaluated in 2007, 34 years
after her initial diagnosis. Her medications included vita-
min K 10 mg twice a week, calcitriol 0.25 mcg daily, beta-
carotene 40,000 IU daily, vitamin A 10,000 IU daily, vita-
min E 400 IU daily, vitamin B6, vitamin B12, calcium,
magnesium and eye drops.
On physical exam her weight was 56.5 kg. She had mild
bilateral scleral icterus. Cranial nerve exam was normal
apart from decreased visual acuity on the right side. The
gait was wide-based. Romberg test was positive but she
had no dysmetria and no dysdiadochokinesia. Sensory
exam was remarkable for decreased vibration sense in
upper and lower limbs and decreased position sense in
the lower limbs. Pain sensation was normal. Motor exam
showed normal tone and power in major muscle groups
with absent knee reflexes. The Babinski sign was negative.
Cardiovascular exam was unremarkable, specifically the
heart rhythm was regular and there was no evidence of
congestive heart failure. The rest of the physical examina-
tion was unremarkable.
Lab evaluation included a normal white blood cell count,
normal hemoglobin concentration, normal mean red
blood cell volume with a slightly elevated reticulocyte
count at 112 × 109/L (normal 10 to 100 × 109/L). The
blood film showed acanthocytosis (Figure 1). Serum con-
centrations of 1,25-dihydroxy-vitamin D and ionized cal-
cium were normal. Serum vitamin E was low at <5 μmol/
L (normal 18–29 μmol/L). International normalized ratio
of prothrombin time was normal at 1.1. Total bilirubin
was slightly elevated at 27.7 μmol/L (normal 3.4–17.1
μmol/L), while direct bilirubin, serum transaminases,
gammaglutaryl transferase, albumin and total protein
were normal. Serum creatine kinase was elevated at 211
Acanthocytes on the peripheral blood smear of case #1 Figure 1
Acanthocytes on the peripheral blood smear of case #1.Orphanet Journal of Rare Diseases 2008, 3:19 http://www.ojrd.com/content/3/1/19
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mmol/L (normal 26–140 mmol/L). Serum thyrotrophin,
progesterone and 17-OH-progesterone were within nor-
mal limits for age and sex. No changes in treatment were
recommended.
Case #2
In 1976, a 16-year old girl presented with progressively
worsening coordination. During infancy, her persistent
diarrhea resolved with the institution of a low-fat diet. At
age 11, routine blood tests revealed acanthocytosis with
undetectable plasma cholesterol and triglyceride, which
together with normal parental lipid profiles suggested a
diagnosis of ABL. Oral vitamin A 25 000 IU daily, 25-
hydroxy vitamin D 10 000 IU daily, and vitamin K 5 mg
daily were prescribed. At age 16, she began to experience
generalized weakness and impaired balance. Neurological
examination revealed mild dysarthria, reduced muscle
bulk, bilateral proximal muscle weakness, absent deep-
tendon reflexes, upgoing plantar reflexes, reduced sensi-
tivity to light touch with loss of proprioception and vibra-
tion sense in a glove-and-stocking distribution, mild
intention tremor, dysdiadochokinesia in upper and lower
limbs, a wide-based ataxic gait and positive Romberg sign
[8]. Evoked motor unit potentials in the right extensor
digitorum brevis were decreased (30% of the lower limit
of normal) and electron microscopy of the sural nerve
showed a marked reduction in large myelinated fibres [8].
Plasma creatine kinase was 314 IU/L (normal <45 IU/L).
Plasma triglycerides and cholesterol were markedly
decreased (1.8 [normal 5.2] and <0.1 [normal 1.3] mmol/
L, respectively) while VLDL and LDL fractions were absent
on lipoprotein electrophoresis. Plasma, erythrocyte and
adipose tissue vitamin E levels were undetectable. Vitamin
E deficiency was diagnosed. High-dose oral vitamin E
therapy at 800 mg/day was added to her treatment in
1981, and was progressively titrated to her current dose of
14 400 IU (220 IU/kg).
She was followed yearly and re-evaluated 26 years later in
2007 at age 47. Her health had remained good and she
remained compliant with treatment. Sequencing of the
MTP gene indicated that she was a compound heterozy-
gote for known pathogenic mutations c.2237G>A
(p.G746E) and c.2524A>T (p.K842X) [7]. Neurological
findings had either improved or not progressed. Examina-
tion revealed no dysarthria with normal muscle bulk and
strength. Both tremor and dysdiadochokinesia had dissi-
pated. Gait had improved to the point that she could run.
However, deep-tendon reflexes remained absent and
plantar reflexes were still upgoing. Light touch, vibration
and proprioreception deficient and bilateral dysmetria
persisted, but had not progressed. Evoked motor poten-
tials in the right extensor digitorum brevis had improved
to 75% of the lower limit of normal. Electromyography of
sural and ulnar nerves indicated a mild sensory neuropa-
thy. Serum CK was normal, as were beta-carotene and pro-
thrombin time, while vitamin E was 6 μmol/L (normal
11–46 μmol/L).
Discussion
ABL is a rare autosomal recessive metabolic disorder with
multi-system manifestations. All reported patients have
fat malabsorption, acanthocytosis, low serum cholesterol
and deficiency of serum apo B. Retinitis pigmentosa,
spinocerebellar ataxia and myopathy have complicated
most of the cases. Two reports of possible association with
certain cancers like ileal adenocarcinoma and metastatic
spinal cord glioblastoma [9,10] have been reported and
fatty liver was reported in 4 cases. The clinical presenta-
tion is very heterogeneous and previous reports had sug-
gested that MTP deficiency is not the sole cause of ABL
[11].
ABL is characterized by absent plasma apo B-containing
lipoproteins that results from MTP  mutations [12]. To
date at least 33 MTP mutations have been identified in 43
ABL patients (Figure 2). Absorption of fats and fat-soluble
vitamins are compromised, leading to failure to thrive and
fat-soluble vitamin deficiency [13]. Vitamin E deficiency
is associated with hyporeflexia, reduced proprioception
and vibratory sensation, muscle weakness and a Frie-
drich's-like ataxia [14]. Before the use of high-dose oral
fat-soluble vitamin treatment, many ABL patients devel-
oped neurological complications before the second dec-
ade and some did not survive past the third decade [13].
Homozygous dysfunctional mutations in APOB lead to a
clinically similar disorder called homozygous hypobetali-
poproteinemia (HHBL, OMIM 107730). While obligate
heterozygote parents of HHBL patients have half-normal
plasma levels of apo B and LDL-cholesterol, obligate het-
erozygote parents of ABL patients have normal plasma
lipoprotein profiles. HHBL patients receive similar treat-
ment advice as ABL patients.
Muller and co-workers [15] first reported in 1974 that
high dose oral vitamin E (100 IU/kg) could increase unde-
tectable serum vitamin levels in ABL patients. Thereafter,
short-term efficacy of high-dose oral vitamin supplements
was noted [8,16]. Reports of longer-term treatment in ABL
have been limited. For instance, combined vitamin E and
A therapy initiated before age 2 was reported to markedly
attenuate retinal degeneration 10 years later [17]. Twelve-
year follow-up indicated that high dose oral vitamin E
(100 IU/kg) slowed retinal degeneration [18]. Long-term
high dose vitamin E reduced neurological sequelae in
other vitamin E-deficient diseases, such as chronic
cholestasis [19], autosomal-recessive vitamin E deficiency
(AVED) [20] and short-bowel syndrome [21]. Our obser-
vations over more than a quarter-century suggest thatOrphanet Journal of Rare Diseases 2008, 3:19 http://www.ojrd.com/content/3/1/19
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ultra-long-term high-dose oral vitamin therapy including
vitamin E is associated with arrest of the neurological
complications in at least some patients with ABL. Such
long-term experience in ABL is relevant particularly since
pharmacological MTP inhibition has recently been pro-
posed as a therapeutic option for patients with severe
hypercholesterolemia [22]. Interestingly, coronary arter-
ies of ABL patients appear to be free of atherosclerotic
lesions [23].
Gastrointestinal manifestations of ABL include diarrhea
and fat soluble vitamin deficiency, which are consistent
features in all reported cases. These manifestations usually
develop during infancy and are worsened with a diet rich
in fat. The diarrhea subsides later in part because patients
learn to avoid fatty foods. However, the low serum levels
of fat soluble vitamins continue, because the plasma
transport and delivery of these vitamins to tissues depends
almost exclusively (for vitamin E and beta-carotene) or in
part (for vitamins A, D, and K) on intact synthesis and
secretion of apo B-containing lipoproteins. Supplementa-
tion with high dose vitamin E results in increased serum
vitamin levels to not more than 30% of the lower limit of
normal. On the other hand, high doses of vitamin A ther-
apy can normalize serum levels. This reflects the fact that
despite impaired absorption and transport from the intes-
tine, subsequent transport of vitamin A in plasma by reti-
nol-binding protein is not impaired in ABL.
Hepatic manifestations of ABL include elevated serum
transaminases with hepatomegaly due to hepatic steatosis
[24,25], although neither of the two patients reported
here had these findings. Cirrhosis has been reported in a
few cases and one patient required transplantation for
hepatic cirrhosis; post transplantation the serum lipopro-
tein profile increased to normal levels, however the fat
absorption defect continued as the mutant MTP remains
expressed in the intestine [26]. Liver biopsies in patients
Genetic map of MTP mutations in patients with abetalipoproteinemia Figure 2
Genetic map of MTP mutations in patients with abetalipoproteinemia. The map shows the genomic structure of 
MTP gene. Black boxes represent exons; dotted lines point to mutation positions. Above the map are single-nucleotide and 
small insertion-deletion mutations. Nucleotide position in reference to the first ATG of MTP cDNA (GenBank Accession No. 
NM_000253) are shown. Directly under the linear map are splicing mutations. The position relative to the intron-exon bound-
ary is shown numerically. Larger deletions are shown as horizontal lines below the linear map, with the span of the deleted 
region indicated by text label.
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with ABL have shown marked steatosis that may be
reflected in raised serum transaminase concentrations
[27].
Hematologic manifestations of ABL include acanthocyto-
sis. These abnormal shaped cells comprise 50% or more
of circulating erythrocytes and were among the earliest
laboratory features of the disorder (see Figure 1). Their
structure inhibits rouleaux formation, leading to
extremely low erythrocyte sedimentation rates. Anemia
has been reported in some cases of ABL [28]. The likely
cause was deficiencies of iron, folate, and other nutrients
secondary to fat malabsorption. Hemolysis which appears
to result from accelerated hydroperoxidation of fatty acids
secondary to tocopherol deficiency may also contribute to
anemia [24]. Elevated prothrombin time, and interna-
tional normalized ratio due to vitamin K deficiency, was
reported in several cases [24]. In two cases, significant gas-
trointestinal bleeding associated with severe vitamin K
deficiency was present in infancy or childhood [24].
Neurological involvement in ABL may be the most serious
clinical manifestation. In ABL both central and peripheral
nervous systems are affected; patients can have either
upper or lower motor neuron findings or both. The pri-
mary driving pathology is demyelination [25]. The onset
of neurologic disease usually begins in the first or second
decade of life and in the past often progressed to cata-
strophic disability, although some patients inexplicably
escaped serious affliction until much later in life [25]. The
long-term clinical results of vitamin E therapy from mul-
tiple previous studies show improvement in neurologic
dysfunction with vitamin E treatment and early therapy
before the age of 16 months prevents neurologic dysfunc-
tion [8,16]. In both cases we have presented, high-dose
oral vitamin E replacement appeared to be associated with
long-term stabilization of neurologic status, although we
appreciate the anecdotal – and perhaps non-generalizable
– nature of this observation.
Muscle involvement in ABL affecting both striated and
smooth muscle has been reported in some patients, and
furthermore was the cause of premature death cases
among a few ABL patients [28-30]. While the etiology of
myopathy is unclear, myositis appeared to be related to
ceroid pigment deposition, while muscle weakness could
possibly be related to vitamin E deficiency and neuropa-
thy. A quadriceps muscle biopsy performed on a 26 year
old male ABL patient who presented with sudden onset of
severe weakness revealed ceroid pigment in the muscle
fibers [30]. The etiology of myopathy in that case remains
unclear due to preserved myofilaments, a feature not con-
sistent with myopathy due to vitamin E deficiency [30].
Death related to cardiomyopathy has been reported in a
10 year old male ABL patient and a 36 year old female ABL
patient [28,29]. Autopsy of the male patient showed
perinculear deposits of lipochrome pigment in cardiomy-
ocytes, suggesting tocopherol deficiency. A male patient of
Northern European descent (Patient 8 in Additional file
1), died at the age of 18 due to respiratory failure related
to neuropathy/myopathy; no autopsy findings were
reported.
Ophthalmic involvement in ABL is variable and appears
to cover a wide range of symptoms and ophthalmic man-
ifestations [31]. The most prominent abnormality is pig-
mentary retinal degeneration. Most patients have loss of
night vision early in the course of disease, while some
patients also present with loss of color vision. The retinop-
athy often produces slowly enlarging annular scotomas
with macular sparing, such that patients are relatively una-
ware of the progression of the disease. Complete loss of
vision can ultimately occur [31]. Fundoscopic examina-
tion reveals an atypical pigmentation of the retina charac-
terized by small, irregularly distributed, white spots.
Electroretinogram and fluorescein angiography investiga-
tions have shown the retina to be affected in asympto-
matic ABL patients [31].
The mechanism underlying the retinopathy in ABL is not
clear. Results from previous studies are inconsistent. A
report of results of up to 18 years of follow-up of six ABL
patients showed that high dose oral vitamin E therapy
(47–172 mg/kg/day) not only prevented the development
of retinopathy but also appeared to arrest the progression
of retinopathy [18]. In 2001, another study of 10 ABL
patients followed for a mean of 11.7 years showed that
combined vitamin A and E supplementation that was ini-
tiated prior to 2 years of age markedly attenuated the
severe retinal degeneration. Yet, fundoscopic and func-
tional retinal changes can occur despite early treatment.
Of note, all ABL patients who received vitamin therapy
prior to 2 years of age were free of the neurologic and sys-
temic complications that are usually associated with
untreated ABL [17]. Other reported abnormalities
include, ophthalmoplegia, anisocoria, nystagmus, strabis-
mus and ptosis. Although the pathogenetic mechanism
for these symptoms is unclear, a neurological basis was
suggested.
In addition to ptosis, case #1 developed a unilateral cor-
neal ulcer after oral vitamin A was discontinued. How-
ever, her symptoms did not improve following re-
institution of vitamin A supplementation. A previous
report described an ABL patient with mild xerophthalmia
[32]. Corneal ulceration is unusual among ABL patients.
It is of interest that reproductive system manifestations
seem to be rather minimal in ABL, indicating that in the
absence of LDL, there is sufficient capacity for synthesisOrphanet Journal of Rare Diseases 2008, 3:19 http://www.ojrd.com/content/3/1/19
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and secretion of steroid hormones, including sex steroids,
provided by HDL. One study evaluating the endocrine
function in a 37 year old female ABL patient of Greek ori-
gin who was diagnosed at age 5 years after instituting die-
tary modifications, found that serum progesterone and 17
(OH) progesterone are low at both exams as well as serum
progesterone at day 21 of the menstrual cycle was below
normal [33]. In addition, in context of low serum choles-
terol one might expect a low fertility rate among ABL
patients. However, successful pregnancy has been
reported on several occasions, as seen with case #1
[31,34,35].
Prognostic factors predicting disease course
Previous case reports have variably suggested links
between age at diagnosis, onset of treatment with low fat
diet and vitamin replacement therapy, type of MTP muta-
tion and APOE genotype with the long-term outcome of
patients with ABL.
Regarding prognosis based upon age at diagnosis, many
ABL patients present in the 2nd to 4th decades, while a few
others present in the 1st and 6th decades. It is possible that
an earlier presentation is due to a more severe phenotype
and perhaps a worse outcome, which would be more
refractory to treatment. However, a later presentation
might also be associated with a more severe outcome due
to a longer period of untreated vitamin deficiency, espe-
cially during growth and development.
Regarding the potential relationship between the type of
MTP mutation and long-term outcome, the current pau-
city of information makes it difficult to predict outcomes
based on MTP genotype (Additional file 1). Also, regard-
ing a possible relationship between APOE genotype and
clinical progression of disease, a recent meta-analysis
identified a linear relationship of APOE genotype with
plasma LDL cholesterol [36]. On the background of APOE
E2 homozygosity, some missense mutations of MTP with
mild to moderate effects on protein structure and function
have been suggested to lower plasma LDL cholesterol lev-
els more dramatically (see patient 19 in Additional file 1)
[37]. In another report that included information about
APOE genotype in six ABL patients, the E4/E2 genotype
seemed to be associated with less favourable outcomes
[7].
Long term treatment and follow-up of ABL
The current standard treatment for ABL is dietary modifi-
cation and replacement of fat soluble vitamins. A low fat
diet has been shown to improve steatorrhea associated
with fat malabsorption and allow absorption of other
nutrients essential for growth and development. High
dose oral fat soluble vitamin supplementation has anec-
dotally been associated with improved clinical outcomes.
High dose oral vitamins are thought to bypass the intesti-
nal chylomicron assembly pathway via the portal circula-
tion (medium-chain triglyceride pathway).
Oral vitamin E is typically given in daily doses ranging
from 2400 to 12000 IU. Plasma vitamin E levels might
not accurately reflect the whole body content of vitamin E
and thus the adequacy of vitamin replacement may be dif-
ficult to gauge from serum concentrations [38]. In one
study, serum vitamin E concentrations, which were ini-
tially undetectable in all ABL patients, became measurable
after oral supplementation, although they never reached
the normal range [16]. Furthermore, needle aspiration of
adipose tissue showed that high doses of vitamin E (150
mg/kg body weight daily) were associated with increased
tissue levels of α-tocopherol in almost all ABL patients.
This was associated with ameliorated neurologic symp-
toms in older subjects and possible protection from neu-
rologic pathology, if supplement is started early enough
[38]. Therefore, the serum vitamin E level can be used to
monitor compliance and adequacy of therapy.
High doses of vitamin A (100–400 IU/kg/day) are needed
to alleviate the deficiencies; the dosing can be variable and
titration can be guided by serum carotene concentrations.
Vitamin A toxicity was reported in one patient. This
patient developed papilledema a few days after introduc-
tion of vitamin A therapy, while her serum vitamin A level
was within normal limits [39].
Vitamin D deficiency is not consistently described among
ABL patients. However, low serum ionized calcium, vita-
min D and bony abnormalities have been described [33],
and thus vitamin D replacement (1000 mg daily) should
be considered in all ABL patients. An abnormal coagula-
tion profile with prolonged prothrombin time and
increased international normalized ratio has been
reported in many ABL patients: two patients had severe
gastrointestinal bleeding. In addition vitamin E absorp-
tion can exacerbate the deficit in vitamin K therefore,
replacement of vitamin K is necessary (5 mg daily). Other
supplementary nutrients like iron, folic acid can also be
considered. Patients need to be followed regularly for
evaluation of symptoms and complications, and to mon-
itor compliance with therapy.
Conclusion
In summary, ABL is a rare disease of lipoprotein metabo-
lism that has drawn attention to the importance of MTP in
the assembly and secretion of apo B-containing lipopro-
teins. Without treatment, ABL symptoms can be debilitat-
ing in most of the patients and life expectancy is expected
to be reduced. Current evidence suggests that early treat-
ment with high oral doses of combined vitamin A and E,
if introduced early enough, can reduce the potential sever-Orphanet Journal of Rare Diseases 2008, 3:19 http://www.ojrd.com/content/3/1/19
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ity of neuropathy and retinopathy. Furthermore, anecdo-
tal evidence, such as the history of the two patients
reported here, suggests that vitamin replacement treat-
ment can reduce morbidity and delay early mortality asso-
ciated with ABL. There is still a need for novel therapeutic
approaches to ABL, since vitamin therapy alone is not suf-
ficient to completely control or cure this disease.
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